A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
NCT 06560645 Brief Summary This is a Phase 1 study to determine…
Read more arrow_forwardNCT 06560645 Brief Summary This is a Phase 1 study to determine…
Read more arrow_forwardNCT 03157128 Brief Summary This is an open-label, first-in-human study designed to…
Read more arrow_forwardNCT 06063681 Brief Summary This is an open-label, dose-escalation, multi-center phase 1…
Read more arrow_forwardNCT 05205109 Brief Summary This is a study of ATG-037 Monotherapy and…
Read more arrow_forwardNCT 04913285 Brief Summary The purpose of this study is to evaluate…
Read more arrow_forwardNCT 05487235 Brief Summary The purpose of this study is to evaluate…
Read more arrow_forwardNCT 04449874 Brief Summary This is a Phase I dose-escalation and dose-expansion…
Read more arrow_forwardNCT 06004245 Brief Summary This is a first-in-human, Phase I, open-label, multicenter,…
Read more arrow_forwardNCT 06004245 Brief Summary This is a first-in-human, Phase I, open-label, multicenter,…
Read more arrow_forwardNCT 06326411 Brief Summary This is a two-part Phase 1, open label,…
Read more arrow_forward